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2053life-style risk factors relating to the fact that cannabis
consumption is frequently associated with tobacco
use and to some festive habits in young males (3). The
higher prevalence of intracranial arterial stenosis as a
cause of IS in CU in our series is in accordance with
the potential involved mechanisms of stroke in CU
represented by reversible cerebral vasoconstriction,
and impairment of cerebral mitochondrial respiration
induced by tetrahydrocannabinol (4,5). The revers-
ibility of vasoconstriction was also described in
peripheral arteritis associated with cannabis use (3).
Our data demonstrate that a favorable functional ca-
pacity is common in young patients suffering from
stroke independently of cannabis use that is likely
due to age-related enhanced brain plasticity. How-
ever, in the whole series, 18% of patients retained
signiﬁcant disability, along with 5 deaths.
Fighting stroke must remain a priority, including in
young adults. The ﬁrst step may be to inform the
public regarding the potential occurrence of stroke
associated with cannabis use and other life-style risk
factors (3), particularly nowadays when cannabis use
is encouraged by new legislations worldwide.
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APOC3 Loss-of-Function
Mutations With
Plasma Lipids and
Subclinical AtherosclerosisThe Multi-Ethnic BioImage StudyIn 2008, Pollin et al. (1) identiﬁed 1 mechanism of
lowering triglyceride-rich lipoproteins among the
Lancaster Amish, loss of apolipoprotein C-III (APOC3)
gene function, which was associated with reduced
subclinical atherosclerosis (i.e., coronary arterial cal-
ciﬁcation on cardiac computed tomography). We
recently extended these observations to show that
APOC3 loss-of-function mutations also reduce risk
for clinical atherosclerotic cardiovascular disease
(ASCVD) (2,3). Here, we address 2 questions related to
mutations that reduce APOC3 function: 1) do these
mutations also associate with lower plasma low-
density lipoprotein cholesterol (LDL-C); and 2) do
these mutations reduce subclinical atherosclerosis in
the general population, particularly in individuals
with ancestry outside of Europe?
We studied 6,699 individuals of European, African,
Asian, and Hispanic ancestries from the BioImage
Study (BioImage Study: A Clinical Study of Burden of
Atherosclerotic Disease in an At-Risk Population,
NCT00738725), a prospective, observational study
aimed at characterizing subclinical atherosclerosis in
U.S. adults (55 to 80 years old) at risk for clinical
ASCVD (4). We genotyped 4 APOC3 (NM_000040.1)
loss-of-function mutations (IVS2þ1G/A, A43T, R19X,
IVS3þ1G/T) using the Illumina HumanExome Bead-
Chip Array v1.1 (Illumina, San Diego, California).
Written informed consent was obtained from all
study participants according to a protocol approved
by the Western Institutional Review Board, Olympia,
Washington. Fasting blood lipids were measured
at the baseline examination. Blood lipids were
adjusted for the presence of statin medications
to reﬂect the observation that statins, on average,
reduce total cholesterol by 20% and LDL-C by 30% (5).
Noninvasive assessments for subclinical athero-
sclerosis (coronary arterial calciﬁcation [CAC],
carotid plaque, and carotid intima media thick-
ness [CIMT]) were performed at the baseline
examination on a mobile imaging facility as previ-
ously described (4).
A total of 6,395 subjects passed all quality-control
measures. Variant calling was performed using
TABLE 1 Association of APOC3 Loss-of-Function Mutation Carrier Status With Blood Lipid Levels and Subclinical Atherosclerosis
Noncarriers
(n ¼ 6,331)
Carriers
(n ¼ 64) Effect Estimate 95% CI p Value
Blood lipids
Triglycerides, mg/dl* 166.1  96.2 91.2  44.1 43.7% 36.6 to 49.9 1.83  1021
HDL cholesterol, mg/dl 55.6  15.2 66.6  15.0 þ11.1 7.6 to 14.6 3.55  1010
LDL cholesterol, mg/dl 130.3  36.4 131.6  35.8 þ1.5 7.4 to 10.3 0.75
Subclinical atherosclerosis
Coronary arterial calciﬁcation,
Agatston units†
46.0 (0.0 to 245.0) 29.0 (0.0 to 227.5) 27.9 51.1 to 4.7 0.019
Carotid plaque, mm2† 183.8 (0.0 to 555.9) 112.8 (0.0 to 367.2) 8.7 73.5 to 56.0 0.79
Carotid intima media thickness, mm* 0.76  0.16 0.74  0.13 1.7% 6.3 to 3.0 0.47
Values are represented as effect estimates (95% conﬁdence intervals) between APOC3 loss-of-function mutation carriers and noncarriers after adjustment for covariates. Covariates used were age, sex,
ancestry, and principal components of ancestry. *Effect estimates for triglycerides and carotid intima media thickness were derived from natural log transformation and are expressed as percent difference in
carriers compared with noncarriers. †Effect estimates for coronary arterial calciﬁcation and carotid plaque derived from median quantile regression and represent differences in medians. Therefore, summary
statistics of the distributions in noncarriers and carriers are represented as median (interquartile range).
CI ¼ conﬁdence interval; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
Letters J A C C V O L . 6 6 , N O . 1 8 , 2 0 1 5
N O V E M B E R 3 , 2 0 1 5 : 2 0 5 2 – 8
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zygous carriers of APOC3 loss-of-function mutations
(25 IVS2þ1G/A, 25 A43T, 13 R19X, 1 IVS3þ1G/T;
combined minor allele frequency of 0.5%) were
identiﬁed. Principal components were derived from
a set of high-quality, independent variants on the
genotyping array using Eigenstrat as has previously
been done (3,5). To minimize confounding from
systematic differences in allele frequencies by trait,
we reduced the observed genetic variation to the
top eigenvectors derived from the sample covari-
ance matrix. To test the association of APOC3 loss-
of-function mutation with an outcome, linear
regression was used for triglycerides, LDL-C, and
high-density lipoprotein cholesterol (HDL-C), and
CIMT; triglycerides and CIMT were natural
log-transformed. And given the bimodal, skewed
distributions of CAC (primary outcome) and carotid
plaque, median quantile regression was used for
these 2 variables. Age, sex, ethnicity, and principal
components of ancestry were used as covariates in
all analyses. Given a 2-sided alpha threshold of
0.05, we have >80% power to detect an effect
size of 0.16% of variance explained for analyzed
traits.
Among carriers and noncarriers of the APOC3
loss-of-function mutations, there were no signiﬁ-
cant differences in age, sex, hypertension, diabetes
mellitus, body mass index, current smoking, aspirin
use, or statin use. There were no signiﬁcant dif-
ferences in proportions of carriers amongst each
ethnicity group (p > 0.20). We replicated the
ﬁnding that APOC3 loss-of-function mutations were
associated with reduced triglycerides (43.7%;
p ¼ 1.83  1021) and increased HDL-C (11.1 mg/dl;p ¼ 3.55  1010), with a larger standardized
effect on triglycerides compared with HDL-C
(1.17 SD vs. þ0.73 SD). When accounting for
statin treatment, carriers did not have different
LDL-C concentrations compared with noncarriers
(p ¼ 0.75).
APOC3 loss-of-function mutations were associated
with decreased median CAC score (27.9 U; 95%
conﬁdence interval [CI]: 51.08 to 4.67; p ¼ 0.019)
across all phenotyped participants (n ¼ 5,631); this
effect was consistent in those of European ancestry
(27.5 U; 95% CI: 67.1 to 12.1) and of non-European
ancestry (5.62 U; 95% CI: 39.2 to 27.9). Neither
carotid plaque (p ¼ 0.79) nor CIMT (p ¼ 0.47) (n ¼
5,746) differed between carriers and noncarriers
(Table 1).
In a multiethnic study of U.S. adults, APOC3 loss-
of-function mutation carriers had reduced plasma
triglycerides, higher HDL-C, and a decreased burden
of coronary arterial calciﬁcation. These data support
the notion that APOC3 deﬁciency reduces coronary
atherosclerosis in the general population. Whether
pharmacological inhibition of APOC3 will reduce
ASCVD risk remains to be tested.Pradeep Natarajan, MD, MMSc
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Dual Antiplatelet TherapyIn a post-hoc analysis, Yeh et al. (1) provide evidence
that dual-antiplatelet therapy with thienopyridine
and aspirin, for 30 (vs. 12) months after coronarystenting, had beneﬁcial effects regardless of whether
patients had acute myocardial infarction (MI) or less
acute presentations. In particular, stent thrombosis
was reduced—although bleeding was increased—
similarly in both groups. Clinicians should, however,
consider various elements of the study design when
interpreting results and using the ﬁndings in clinical
practice.
Importantly, the study classiﬁed patients with
unstable angina as having less acute (“no MI”) pre-
sentations. This subset accounted for nearly one-
fourth (22.6%) of the 8,072 patients without MI, or
roughly 1,800 patients—representing more than one-
half of the 3,576 patients with MI. Combining unsta-
ble angina patients within the non-MI group is of
more utility in allowing for conclusions to be drawn
on the MI group, given that the non-MI group repre-
sents a population of patients with a wide range of
risk of subsequent events—and it is unclear whether
the beneﬁcial effects of prolonged treatment was
driven by those at higher risk within this group.
Perhaps a sensitivity analysis could be done, ex-
cluding patients with unstable angina from the non-
MI group, to see if the overall results are affected.
From a more general perspective, the reader may
not immediately recognize that the current analyses
represent a post-hoc subgroup analysis of a previ-
ously completed randomized trial, with randomiza-
tion 12 months after initial enrollment. We would
defend the authors from reﬂexive criticisms that
such analyses are always problematic, but we
also note that whether the ﬁndings are valid, or
due to chance or bias, is always a consideration.
For example, lacking a formal power calculation
linked to antecedent MI status, the discordant
ﬁndings of similarly reduced stent thrombosis
without an interaction, compared to differential
reduction of major adverse cardiovascular and ce-
rebrovascular events with an interaction, have un-
certain implications.
Finally, as a speciﬁc methodological issue, the data
in Figure 1 in the paper by Yeh et al. (1) indicate that
(25,682 total minus 5,844 not eligible equals) 19,838
patients were eligible for randomization, but 8,190
were not randomized at 12 months for the reasons
stated. Given that this group represents (8,190
divided by 19,838 equals) 41.3% of eligible patients, it
would be useful to know whether pertinent baseline
characteristics (including the distribution of patients
in MI and non-MI groups) differ between analyzed
and excluded patients, for better understanding the
overall results.
